Iron and oxidative stress in renal insufficiency

American Journal of Nephrology

Volumn 24, Issue 6, 2004, Pages 569-575

  Lim, Chun Soo ^a   Vaziri, Nosratola D ^b  

^a Seoul National University College of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidant enzyme; Chronic renal failure; Lipid peroxidation; NAD(P)H oxidase; Nitric oxide; Oxidative stress; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; CATALASE; ENZYME; GLUTATHIONE PEROXIDASE; IRON; IRON DEXTRAN; MALONALDEHYDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ASSAY; ENZYME SUBUNIT; HEMOGLOBIN DETERMINATION; HYPERTENSION; IRON BLOOD LEVEL; IRON OVERLOAD; KIDNEY PARENCHYMA; LIPID PEROXIDATION; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TRANSFERRIN BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; CATALASE; GLUTATHIONE PEROXIDASE; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; NADPH OXIDASE; NEPHRECTOMY; OXIDATIVE STRESS; PHOSPHOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 13244284948     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082201     Document Type: Article

References (39)

1. Vaziri ND: Role of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004;13:93-99.
2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
3. Agarwal R, Warnock D: Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002;22:479-487.
4. Besarab A: Iron and cardiac disease in the endstage renal disease setting. Am J Kidney Dis 1999;34(suppl 2):S18-S24.
5. Kletzmayr J, Hörl WH: Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002;17(suppl 2):25-29.
6. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. QJM 1994;87:679-683.
7. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002;39:135-141.
8. Massy ZA, Nguyen-Khoa T: Oxidative stress and chronic renal failure: Markers and management. J Nephrol 2002;15:336-341.
9. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK: Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003;63:179-185.
10. Salonen JT, Nyyssönen K, Salonen R: Body iron stores and the risk of coronary heart disease. N Engl J Med 1994;331:1159.
11. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F: Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study. Circulation 1997;96:3300-3307.
12. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212-2217.
13. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ: Dietary iron intake and risk of coronary disease among men. Circulation 1994;89:969-974.
14. Reunanen A, Takkunen H, Knekt P, Seppanen R, Aromaa A: Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med 1995;238:223-230.
15. Landing BH, Gonick HC, Nadorra RL, Hyman CB, Wells TR, Villarreal-Engelhardt G, Mersch J, Agness CL: Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. Pediatr Pathol 1989;9:479-500.
16. Pardo-Mindan FJ, Diez J, Esparza N, Robledo C: Renal siderosis in patients with heart-valve prostheses: Clinical implications. Nephrol Dial Transplant 1990;5:847-850.
17. Zhou XJ, Vaziri ND, Pandian D, Wang ZQ, Mazowiecki M, Liao SY, Oveisi F: Urinary concentrating defect in experimental hemochromatosis. J Am Soc Nephrol 1996;7:128-134.
18. Zhou XJ, Laszik Z, Wang XQ, Silva FG, Vaziri ND: Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000;80:1905-1914.
19. Zainal TA, Weindruch R, Szweda LI, Oberley TD: Localization of 4-hydroxy-2-nonenalmodified proteins in kidney following iron overload. Free Radic Biol Med 1999;26:1181-1193.
20. Schimmel M, Bauer G: Proapoptotic and redox state-related signaling of reactive oxygen species generated by transformed fibroblasts. Oncogene 2002;21:5886-5896.
21. Preece NE, Evans PF, Howarth JA, et al: The induction of autooxidative tissue damage by iron nitrilotriacetate in rats. Toxicol Appl Pharmacol 1988;93:89-100.
22. Ishizaka N, Saito K, Mitani H, Yamazaki I, Sata M, Usui S, Mori I, Ohno M, Nagai R: Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation 2002;106:1840-1846.
23. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, Vita JA: Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103:2799-2804.
24. Lim CS, Vaziri ND: The effect of iron dextran on oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004;65:1802-1809.
25. Vaziri ND, Wang XQ: CGMP-mediated negative-feedback regulation of endothelial nitric oxide expression by nitric oxide. Hypertension 1999;34:1237-1241.
26. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND: Lead-induced hypertension: Interplay of nitric oxide and reactive oxygen species. Hypertension 1997;30:1487-1492.
27. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ: Downregulation of nitric oxide synthase in chronic renal insufficiency: Role of excess PTH. Am J Physiol 1998;274:F642-F649.
28. Deng G, Vaziri ND, Jabbari B, Ni Z, Yan XX: Increased tyrosine nitration of the brain in chronic renal insufficiency: Reversal by antioxidant therapy and angiotensin-converting enzyme inhibition. J Am Soc Nephrol 2001;12:1892-1899.
29. Pagano PJ, Tornheim K, Cohen RA: Superoxide anion production by rabbit thoracic aorta: Effect of endothelium-derived nitric oxide. Am J Physiol 1993;265:H707-H712.
30. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
31. Matés JM, Pérez-Gómez C, Núñez de Castro I: Antioxidant enzymes and human diseases. Clin Biochem 1999;32:595-603.
32. Shah SV, Walker PD: Evidence suggesting a role for hydroxyl radical in glycerol-induced acute renal failure. Am J Physiol 1988;255:F438-F443.
33. Paller MS: Hemoglobin and myoglobin-induced acute renal failure in rats: Role of iron in nephrotoxicity. Am J Physiol 1988;255:F539-F544.
34. Alfrey AC, Froment DH, Hammond WS: Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989;36:753-759.
35. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
36. Stevens L, Stigant C, Levin A: Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dial 2002;15:8-13.
37. Eschbach JW: Current concepts of anemia management in chronic renal failure: Impact of NKF-DOQI. Semin Nephrol 2000;20:320-329.
38. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH: Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001;37:564-572.
39. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002;13:734-744.